Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan

This review aims to elucidate the optimal dosing of angiotensin receptor-neprilysin inhibitor (ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial population characteristics and the mortality benefit observed in the Prospective Comparison of ARNI with angioten...

Descripción completa

Detalles Bibliográficos
Autores principales: Sokos, George G, Raina, Amresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972579/
https://www.ncbi.nlm.nih.gov/pubmed/32021227
http://dx.doi.org/10.2147/VHRM.S197291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972579/
https://www.ncbi.nlm.nih.gov/pubmed/32021227
http://dx.doi.org/10.2147/VHRM.S197291

Ejemplares similares